Latest Viking Therapeutics News & Updates
See the latest news and media coverage for Viking Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company developing metabolic disorder therapeutics
vikingtherapeutics.com- Headquarters
- San Diego, United States
- Founded year
- 2012
- Company type
- Public company
- Number of employees
- 50–200
Last updated
Latest news about Viking Therapeutics
In short: Viking Therapeutics advanced its obesity drug VK2735 into Phase 3 trials while reporting a $158.3 million net loss and a license termination notice.
Company announcements
-
Viking Therapeutics reports Q1 2026 financial results
VANQUISH-1 and -2 trials fully enrolled. Oral VK2735 Phase 3 starts 4Q26. Cash at $603M. Net loss $158.3M.
-
Viking Therapeutics completes enrollment in VK2735 Phase 3 VANQUISH-2 trial
The 78-week study evaluates subcutaneous VK2735 in adults with obesity and type 2 diabetes. About 1,000 patients were randomized to doses or placebo.
-
Viking Therapeutics reports Q4 and year-end 2025 financial results
Announces Phase 3 progress for VK2735 in obesity, plans oral VK2735 Phase 3 in 3Q26, and holds $706M cash. Net loss was $157.7M for Q4 and $358.5M for the year.
-
Viking Therapeutics announces publication of Phase 2 VENTURE trial results
VK2735 shows up to 14.7% weight loss after 13 weeks with no plateau. VK2735 advances in Phase 3 VANQUISH trials.
Media coverage
-
Ligand Pharma Ends TR‑Beta License With Viking Therapeutics
On April 24, 2026, Ligand Pharmaceuticals notified Viking Therapeutics that it will terminate their TR‑Beta Program license, covering assets including VK2809 and VK0214, effective May...
-
Viking Therapeutics Announces Two Poster Presentations at European Congress on...
Poster Presentations Highlight Data from 13-Week Phase 2 VENTURE-Oral Trial of VK2735 and Participant Characteristics from Phase 3 VANQUISH-1 Trial of Subcutaneous VK2735 SAN DIEGO...
-
Why Viking Therapeutics (VKTX) Is Down 8.4% After Expanding VK2735 Phase 3 Obesity Program And Loss
In late April 2026, Viking Therapeutics reported a wider first‑quarter net loss of US$158.33 million...
-
Ligand tries to disembark from part of Viking pact, alleging contract breach
Viking Therapeutics' collaboration with Ligand Pharmaceuticals has sailed into some trouble, with one of the partners keen to jettison part of the pact. | Viking...
Track Viking Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Trending companies
Discover what's making headlines across other trending companies.
Pit
Davis AI
Qutwo
DigiPowerX
Penguin Solutions
Sterling Infrastructure
KIOXIA Corporation
Subquadratic
Tibber
IREN
A24
Hitachi Energy
Ouster
Ormat Technologies
Fabrinet
AOI
WidePoint
Filtronic
Mirum Pharmaceuticals
Capstone Green Energy
AXT
POET Technologies
PurpleFire
Profitable Media
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable
Braze
Optimove
Bluecore